uniQure Just Filed the First Gene Therapy BLA for Huntington’s

Huntington’s disease kills neurons. Slowly, irreversibly, and with no approved treatment that does anything to slow the process. That may be about to change.

On September 2, 2026, uniQure (NASDAQ: QURE) submitted a Biologics License Application to the FDA seeking accelerated approval of ifezuntirgene inilparvovec, the gene therapy the company has been developing for nearly a decade under the working name AMT-130. The company simultaneously filed a Marketing Authorisation Application with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Both submissions rest on three-year data from a Phase I/II study that the company says showed the therapy could meaningfully slow disease progression.

If the FDA accepts the BLA for priority review, a decision could arrive within roughly eight months.

A Road That Was Anything But Straight

The story of how uniQure got here is worth telling on its own.

In late 2024, uniQure had been working under FDA feedback that Phase I/II data compared to an external control could potentially support a BLA under the accelerated approval pathway. Then came a January 30, 2026 Type A meeting. The FDA reversed, stating it could not agree that data from the Phase I/II studies, compared to an external control, were sufficient to provide the primary evidence of effectiveness required to support a marketing application, and it strongly recommended a prospective, randomized, double-blind, sham-surgery-controlled study. For a small developer, that outcome would normally signal years of delay and hundreds of millions in added expense. The stock fell sharply on March 2, 2026, when the company disclosed the final meeting minutes confirming the agency’s position.

uniQure did not concede. The company requested a Type B meeting for the second quarter of 2026 and kept engaging. In June 2026, uniQure said the FDA communicated that the three-year Phase I/II analysis would be acceptable as the primary basis of a BLA for accelerated approval. The FDA also indicated it wanted to align on the confirmatory study design prior to submission, including consideration of a concurrent control on standard-of-care therapy instead of a sham procedure. That change in the confirmatory trial design matters enormously: sham brain surgery is an extraordinarily high bar to clear in trial enrollment.

What the Data Show

AMT-130 uses uniQure’s miQURE platform, a microRNA-based approach delivered in a single neurosurgical procedure directly into the striatum via MRI-guided, convection-enhanced stereotactic delivery. The therapy is designed to lower huntingtin protein by targeting HTT mRNA. Patients receive it once.

At three years, the high-dose cohort showed 75% slowing of disease progression on the composite Unified Huntington’s Disease Rating Scale versus propensity score-matched external controls drawn from the Enroll-HD natural history dataset, with a p-value of 0.003. Cerebrospinal fluid neurofilament light levels, a marker of neuronal injury, fell by a mean of 8.2% in treated patients. Based on uniQure’s latest guidance, topline four-year data from the Phase I/II study are expected in September 2026.

AMT-130 already holds Regenerative Medicine Advanced Therapy, Breakthrough Therapy, and Fast Track designations from the FDA. uniQure has said it is the first therapeutic candidate in Huntington’s disease to receive RMAT designation.

Why the Market Opportunity Is Larger Than the Patient Count Suggests

Huntington’s disease affects roughly 41,000 symptomatic people in the United States, a figure that understates the broader population at risk of inheriting the mutation. The treatment market for Huntington’s has been estimated around $1.7 billion in 2026 and, by some forecasts, could approach $6.5 billion by 2035 as disease-modifying therapies enter the picture. Gene therapies are projected by some market researchers to be the fastest-growing segment, with compound growth above 28%. A one-time surgical treatment with multi-year durability carries very different pricing economics than a daily pill.

uniQure reported $586.6 million in cash, cash equivalents, and investment securities as of March 31, 2026, with management at the time estimating runway into the second half of 2029. Since then, the company reported that a $259 million follow-on offering extended its cash runway into 2030.

The Risks Are Real

Accelerated approval is contingent on the FDA’s 60-day filing review, and acceptance for priority review is not guaranteed. The agency could request additional information, lengthening the clock. Long-term durability data beyond three years remains an open question, and the safety profile of direct intracranial delivery will receive close scrutiny. A confirmatory trial must still be designed, funded, and initiated. Failure on that study after an accelerated approval could lead to withdrawal.

Competitive pressure is building too. PTC Therapeutics and its partner Novartis are advancing votoplam, an oral HTT mRNA splice modulator. Several other programs in RNA interference and antisense oligonucleotides remain in development. uniQure’s one-time surgical approach carries clear differentiation but also a delivery complexity that symptomatic-care alternatives do not.

The Bigger Picture

No drug has ever received approval for slowing Huntington’s disease. If AMT-130 clears the FDA, it would be the first disease-modifying treatment in the history of a condition that currently offers patients nothing beyond symptom management. That is a genuinely rare category of unmet need, and regulators have signaled, through every designation they have granted, that they understand it.

uniQure is worth watching closely over the next eight months. The filing review window alone will generate material news flow, and four-year data in September 2026 could reinforce or complicate the efficacy case. This is exactly the kind of inflection point where the gap between a stock’s price and its potential tends to narrow quickly, in either direction.